Eliquis (Apixaban), Pradaxa (Dabigatran), and Xarelto (Rivaroxaban) & Cutaneous Small-Vessel Vasculitis

    Basic Details
    Status
    Complete
    Last Updated
    Monday, November 2, 2020
    Health Outcome(s)
    cutaneous small-vessel vasculitis
    Purpose
    Drug and Outcome Analysis
    Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
    No